broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K13514097-001-04-6 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.861266 | 0.115528 | 0.073044 | 1 | 2.372146 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000926 |
BRD-K13662825-001-07-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.427661 | 0.660118 | 0.543718 | 0.673087 | 0.009224 | 0.172515 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000926 |
BRD-K14109347-001-03-4 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.189077 | 0.435011 | -0.015519 | 1 | 0.005257 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000926 |
BRD-K15179879-001-03-2 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.087647 | 5.075059 | 0.482513 | 0.603532 | 0.147399 | 0.153105 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000926 |
BRD-K15600710-066-05-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.160594 | 6.688307 | 0.518286 | 0.747298 | 0.528718 | 0.560256 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000926 |
BRD-K16730910-001-10-7 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.795756 | -0.030096 | -0.044039 | 0.897399 | 0.106705 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000926 |
BRD-K17555800-003-02-3 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.862419 | 0.053312 | -0.053225 | 0.919074 | 0.000094 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000926 |
BRD-K17610631-001-03-3 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 2.939353 | 14.820418 | 0.897461 | 1 | 0.634023 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000926 |
BRD-K17743125-001-08-4 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.817362 | 0.80986 | 0.001635 | 0.923695 | 0.179506 | null | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000926 |
BRD-K19540840-001-09-4 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.685992 | -0.045343 | -0.012078 | 0.850893 | 0.008402 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000926 |
BRD-K19687926-001-04-1 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.84551 | 0.295547 | -0.009402 | 0.926921 | 0.119567 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000926 |
BRD-K19796430-001-05-6 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.933888 | -0.058324 | -0.04796 | 0.970172 | 0.002655 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000926 |
BRD-K22064724-001-01-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.078972 | 3.593365 | 0.779408 | 0.732986 | 0.599977 | 0.629379 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000926 |
BRD-K23228615-001-02-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.307644 | 0.211346 | 0.351684 | 0.627425 | 0.035619 | 3.270664 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000926 |
BRD-K23984367-001-07-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.316613 | 0.468507 | -0.014015 | 1 | 0.533558 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000926 |
BRD-K26657438-001-15-2 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.888004 | -0.118669 | -0.003102 | 0.907873 | 43,264.290754 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000926 |
BRD-K28822270-001-03-7 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.717374 | 0.195533 | 0.052281 | 0.879818 | 0.427479 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000926 |
BRD-K29905972-001-06-3 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 2.335691 | 2.117616 | 0.684887 | 1 | 7.198969 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000926 |
BRD-K30577245-001-05-0 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.556046 | -0.185991 | -0.01808 | 1 | 0.003589 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000926 |
BRD-K31698212-001-02-9 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.969749 | -0.318895 | -0.028264 | 0.97563 | 13.935124 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000926 |
BRD-K31928526-001-02-1 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 9.833873 | 11.214635 | -0.581348 | 1 | 12.634225 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000926 |
BRD-K33379087-001-07-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.160551 | -0.00063 | -0.013314 | 1 | 181,793,021,454,968,830,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000926 |
BRD-K33610132-001-02-9 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.832341 | 0.140148 | 0.036799 | 0.91445 | 0.05762 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000926 |
BRD-K33622447-066-01-9 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.752455 | 1.815423 | 0.269051 | 0.90485 | 0.240029 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000926 |
BRD-K35520305-001-16-9 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.846069 | -3.178238 | 0.104134 | 0.880604 | 1.133798 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000926 |
BRD-K36627727-001-05-4 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.240414 | 0.548088 | 0.109328 | 1 | 0.054155 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000926 |
BRD-K36788280-001-01-2 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.837511 | -3.420409 | 0.162579 | 0.892514 | 0.374398 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000926 |
BRD-K37379014-001-02-0 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.966959 | -0.240328 | -0.000534 | 0.974855 | 0.243796 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000926 |
BRD-K38332599-001-01-3 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.878166 | 2.379143 | 0.113355 | 0.949448 | 0.178336 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000926 |
BRD-K38527262-300-01-0 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.083569 | 6.940106 | 0.817201 | 0.74764 | 0.636046 | 0.65303 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000926 |
BRD-K39974922-001-04-3 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.879387 | -0.005888 | 0.001341 | 0.939462 | 0.288225 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000926 |
BRD-K41859756-001-06-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.957106 | 0.395699 | 0.011658 | 0.984768 | 0.134786 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000926 |
BRD-K42495768-001-01-7 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.889812 | -3.566807 | -0.027717 | 0.91906 | 0.760836 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000926 |
BRD-K42805893-001-04-9 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.478964 | 0.365986 | 0.294976 | 0.846126 | 1.464653 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000926 |
BRD-K42828737-001-03-3 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.153295 | 0.324173 | -0.065418 | 1 | 0.696299 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000926 |
BRD-K42898655-001-01-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.462062 | 1.030241 | 0.262031 | 1 | 0.008234 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000926 |
BRD-K43389675-001-02-1 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.231359 | 4.024992 | 0.184984 | 0.901271 | 2.879775 | 3.360387 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000926 |
BRD-K44227013-001-06-4 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.062095 | 2.273896 | 0.417345 | 0.907839 | 4.064885 | 4.308985 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000926 |
BRD-K44408410-001-17-6 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.488876 | 5.143533 | 0.424722 | 1 | 0.68515 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000926 |
BRD-K44827188-001-06-0 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.838545 | 0.01738 | 0.001911 | 0.948889 | 1,362,095,718,942,724,000 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000926 |
BRD-K46386702-001-02-1 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.644334 | 0.194413 | 0.164974 | 0.799157 | 0.018581 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000926 |
BRD-K49328571-001-15-0 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.075882 | 4.953983 | 0.11356 | 1 | 0.004892 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000926 |
BRD-K49350383-001-14-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.293802 | 2.865557 | 0.424296 | 1 | 0.44566 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000926 |
BRD-K50010139-001-01-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.409929 | 0.133622 | 0.152946 | 0.66075 | 0.007537 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000926 |
BRD-K51313569-001-07-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.915622 | -0.236131 | -0.075686 | 0.978596 | 0.000519 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000926 |
BRD-K51791723-003-01-7 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.37002 | 0.493156 | 0.24482 | 0.658105 | 0.047439 | 0.728729 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000926 |
BRD-K51967704-001-03-6 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.620682 | 0.085134 | -0.143367 | 0.785748 | 0.003495 | null | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000926 |
BRD-K53414658-001-08-2 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.326037 | 0.338645 | 0.218758 | 1 | 0.153199 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000926 |
BRD-K53972329-001-07-0 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.941004 | -0.002961 | -0.002875 | 0.97035 | 2.557274 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000926 |
BRD-K54256913-001-08-7 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.830802 | -0.959581 | -0.128137 | 0.976682 | 0.001657 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000926 |
BRD-K54955827-001-02-2 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.533801 | 1.93372 | 0.584203 | 1 | 0.748106 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000926 |
BRD-K54997624-001-06-0 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.370677 | 5.606854 | 0.545494 | 0.829994 | 0.726851 | 0.925087 | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000926 |
BRD-K55187425-236-05-2 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.639622 | 1.588743 | 0.101759 | 0.905773 | 0.799645 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000926 |
BRD-K56343971-001-14-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.128035 | -0.196201 | -0.058919 | 1 | 0.706101 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000926 |
BRD-K56981171-001-02-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.219157 | 3.400597 | 0.537796 | 0.964445 | 6.922029 | 8.201602 | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000926 |
BRD-K57080016-001-15-9 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.639998 | 0.140788 | 0.072559 | 0.847391 | 0.750053 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000926 |
BRD-K57169635-001-04-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.123016 | 0.373147 | 0.229514 | 0.576336 | 0.098136 | 0.209174 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000926 |
BRD-K58435339-001-03-0 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.685652 | 0.097546 | -0.006096 | 0.8671 | 2.016261 | null | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000926 |
BRD-K58529924-001-01-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.892447 | 0.203502 | 0.000589 | 0.94345 | 0.047872 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000926 |
BRD-K58550667-001-08-7 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.694285 | 0.09269 | -0.056797 | 0.80326 | 0.000008 | null | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000926 |
BRD-K59317601-001-05-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.478936 | 0.893917 | 0.556501 | 0.826413 | 0.418999 | null | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000926 |
BRD-K59369769-001-22-9 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.46515 | 1.736557 | 0.513742 | 1 | 0.059961 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000926 |
BRD-K60866521-001-07-1 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.708511 | -1.064803 | 0.125695 | 0.867744 | 0.04958 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000926 |
BRD-K60997853-001-02-3 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.152196 | 0.264522 | -0.050257 | 1 | 0.388282 | null | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000926 |
BRD-K61192372-001-08-9 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.844748 | -3.313938 | 0.215686 | 0.862761 | 3.267073 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000926 |
BRD-K62196610-001-01-6 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.589555 | 5.616817 | 0.571576 | 1 | 0.156508 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000926 |
BRD-K62200014-003-10-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.075851 | 0.26474 | 0.000615 | 1 | 0.000408 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000926 |
BRD-K62391742-001-09-7 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.038868 | -0.005859 | -0.021072 | 1 | 1.960646 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000926 |
BRD-K62627508-001-01-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.269749 | 3.220297 | 0.450368 | 1 | 0.097316 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000926 |
BRD-K63504947-001-14-7 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.142391 | -0.093853 | -0.050069 | 1 | 60.138491 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000926 |
BRD-K63712959-001-01-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.857294 | -4.256298 | -0.000923 | 0.938338 | 0.040405 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000926 |
BRD-K64052750-001-22-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.798247 | 1.02377 | 0.038835 | 0.84504 | 0.005229 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000926 |
BRD-K64881305-001-03-7 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.387591 | -0.407785 | 0.04646 | 1 | 0.052591 | null | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000926 |
BRD-K66175015-001-12-4 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.342273 | 1.865952 | 0.532828 | 0.655112 | 0.061653 | 0.114416 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000926 |
BRD-K67844266-003-01-9 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.633608 | 2.553586 | 0.335787 | 0.913292 | 1.007081 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000926 |
BRD-K69001009-001-02-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.073354 | -0.240659 | -0.023967 | 1 | 0.117714 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000926 |
BRD-K69694239-001-02-2 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.084435 | 2.025604 | 0.752358 | 0.673033 | 0.312643 | 0.342536 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000926 |
BRD-K69776681-001-03-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.927599 | -0.251107 | -0.039012 | 0.957714 | 0.354778 | null | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000926 |
BRD-K70301465-001-05-9 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.671532 | 0.891074 | 0.15944 | 0.803638 | 0.029371 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000926 |
BRD-K70401845-001-15-7 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.757993 | 1.921065 | 0.114038 | 0.929161 | 0.585145 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000926 |
BRD-K73838513-003-05-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.056521 | 7.492051 | 0.799179 | 0.879713 | 2.901781 | 2.948658 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000926 |
BRD-K74514084-003-09-2 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.897653 | -0.055207 | -0.057801 | 0.94934 | 0.054187 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000926 |
BRD-K75009076-001-02-1 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.10377 | 4.459841 | 0.552497 | 0.928285 | 4.632844 | 4.880891 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000926 |
BRD-K76210423-001-01-6 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.883888 | 0.508429 | -0.107137 | 0.926375 | 0.016307 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000926 |
BRD-K76674262-001-03-3 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.494247 | 2.22727 | 0.234602 | 0.856855 | 0.642007 | 4.765771 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000926 |
BRD-K76908866-001-07-6 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.747868 | -0.153005 | -0.076778 | 0.834284 | 6.636675 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000926 |
BRD-K77625799-001-07-7 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.680206 | 0.251394 | 0.005964 | 0.838123 | 0.069936 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000926 |
BRD-K78431006-001-15-1 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.848596 | -0.742673 | 0.059784 | 0.98936 | 0.000349 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000926 |
BRD-K79254416-001-21-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.954658 | -1.320888 | -0.141203 | 0.984745 | 0.015811 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000926 |
BRD-K81016934-001-02-0 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.10761 | 1.8661 | 0.118913 | 1 | 0.038782 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000926 |
BRD-K81473043-001-19-5 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.94852 | -0.141668 | -0.00554 | 0.965447 | 0.907505 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000926 |
BRD-K82135108-001-04-3 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.120352 | 6.686921 | 0.364141 | 0.825268 | 1.454808 | 1.515993 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000926 |
BRD-K82746043-001-19-3 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | -0.669902 | 1.439854 | 0.377559 | 0.951459 | 16.159426 | 8.95418 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000926 |
BRD-K82818427-001-04-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.040253 | -0.437144 | 0.003581 | 1 | 0.106573 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000926 |
BRD-K83029223-001-01-3 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.269455 | -0.036199 | -0.025304 | 1 | 31,704.935783 | null | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000926 |
BRD-K83988098-001-02-0 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.8969 | -0.01547 | -0.068493 | 0.932088 | 3,565,804,396,455,576 | null | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000926 |
BRD-K85402309-043-01-9 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.270888 | 3.088327 | 0.11024 | 1 | 0.460404 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000926 |
BRD-K85606544-001-09-1 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.792712 | 0.786714 | -0.131084 | 0.918766 | 0.235176 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000926 |
BRD-K86118762-001-01-8 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 0.400023 | 0.391513 | 0.260206 | 0.783886 | 0.507539 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000926 |
BRD-K86972824-001-01-4 | ACH-000926 | HT55_LARGE_INTESTINE | MTS010 | 1 | 1.4313 | 0.677554 | 0.056953 | 1 | 0.81438 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000926 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.